



Guidelines for abstract submission poster presenters

1. GUIDELINES

Abstracts can be submitted via the online abstract submission system on the website. Abstracts should be prepared strictly according to the following instructions. Changes cannot be made after the abstract submission deadline.

For examples of abstracts have a look at the model abstracts, [click here](#).

Content

- Abstracts should include:
 - brief introduction to the research question
 - aim(s) of the study
 - methods used including statistical analysis methods
 - summary of results containing real data and the outcome of statistical analyses
 - conclusions
- Abstracts must report on high quality research in the field of neuropsychopharmacology and/or (applied) neuroscience that has not been published in whole elsewhere.
- Abstracts must be relevant to one of the main topics.
- The statements, particularly in the conclusion section, should be balanced.
- No abbreviations or trade names are allowed in the title. However, the generic name may be used.
- Use standard abbreviations for well-established neuropsychopharmaceuticals. Place unusual abbreviations in parentheses after the full word the first time it appears. Clearly identify all neuropsychopharmaceuticals used.
- A disclosure on potential conflicts of interest (acknowledgement of funding) is requested when submitting an abstract.

Layout

- Abstracts must be submitted in English (UK).
- We encourage you to use the Neuroscience-based Nomenclature in the abstract, more info <http://www.nbn2.org/>
- The title should not exceed 20 words.
- Write the title in lower case letters (except the first letter) and do not put a dot at the end.
- Abstracts should have a minimum of 450 and a maximum of 500 words (excluding references).
- The use of underlined is not permitted. Words that need emphasis should be **bold** or *italics* type.
- Only one table is allowed, please note that graphs and pictures cannot be included. Tables cannot be inserted with copy/paste. Please create your table with the help of the 'table button' (top left, middle button).

References (optional)

- Optionally, you can include up to five references to previous publications. In the body text, a publication should be referred to by a consecutive number between brackets, i.e. [1], [2], [3], [4] and [5]. References indicated in the reference list, that are not linked to the body text will be deleted by the publisher.
- Authors are responsible for the accuracy of references. Only published articles and those in press (the journal should be stated) may be included; unpublished results and personal communications should be cited as such in the body text.



- It is the author's responsibility that the references are provided in accordance with *ENP journal referencing guidelines*. We recommend you to use the [citation machine](#). The guidelines on how to use citationmachine can be found [here](#).

Examples of references

Reference to a journal publication

[1] Chamberlain, S.R., Hampshire, A., Muller, U., Rubia, K., Del Campo, N., 2009. Atomoxetine modulates right inferior frontal activation during inhibitory control. A pharmacological functional magnetic resonance imaging study. *Biol. Psychiatry* 65(4), 550-555.

Reference to the DSM-5

[1] American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders, fifth ed. American Psychiatric Association Publishing, Washington.

Reference to a book

[1] Strunk Jr., W., White, E.B., 1979. *The Elements of Style*, third ed. Macmillan, New York.

Reference to a chapter in a book

[1] Williams, K., 1980. Pharmacological dilemmas in psychiatry, in: Weaver, R., Smith, L.K., *Perspective on psychiatry*, second ed. Theme Press, Cornwall, 301-315.

Reference to a website

[1] McArthur, J., 2014. The link between schizophrenia and dementia, a new perspective. Available from: www.biopsychiatry.com/schizophrenia-dementia. [Accessed: 12 May 2015].

Reference to a DOI

[1] De Jong, A., 2015. Developments in the field of neuropsychopharmacology. *Pharm. Journal*, this issue, <http://dx.doi.org/10.2215.j.pharmjournal.2014.09.003>.

Authors

- Insert the author's initials, last name and institute details as indicated on the on-line form. Do not add any titles or degrees: Prof, Dr, etc.
- The person submitting the abstract should be the author presenting and attending the meeting (presenting author). All communication will be done with the presenting author.

2. REVIEW AND PUBLICATION

Review

An abstract is eligible for review when the abstract is submitted according to the guidelines and on or before the deadline.

All submitted abstracts will be evaluated by a scientific review committee. The author will be informed of the committee's decision by e-mail no later than 15 January 2021. There can be no correspondence about the outcome.

When your abstract is accepted you will have to give a presentation on this abstract at the ECNP Workshop and attend all the sessions.



Publication

The abstracts will be reviewed according to the scientific standard of the journal *European Neuropsychopharmacology* and all accepted abstracts will be published in a supplement to the journal. The supplement will be available on the website www.europeanneuropsychopharmacology.com (free of charge for ECNP members).

The publisher of *European Neuropsychopharmacology* holds all publication rights including copyright.

Abstracts should be received on or before 1 December 2020, 17.00 CET – Central European Time